-
Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D
•
Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the firm’s ongoing commitment to the China market with local media. Speaking to China Daily, Shi emphasized that Sanofi has “always been optimistic about the Chinese market and will continuously expand our investment in China.” Sanofi…
-
XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly & Co., (NYSE: LLY) to provide AI drug discovery services. The deal, valued at up to USD 250 million in total upfront and milestone payments, will involve XtalPi leveraging its AI capabilities and robotics platform to…
-
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
•
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Roche’s MabThera (rituximab), which is used for the treatment of follicular lymphoma (FL), CD20 positive diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). Phase III Study…
-
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for its two drug candidates, SHR-2106 and HRS-1893. SHR-2106: A Pioneering Monoclonal Antibody for Organ TransplantationSHR-2106 is an in-house developed monoclonal antibody (mAb) with no similar product approved…
-
Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion
•
US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which will see Energenx develop and commercialize Galvanize’s products in Greater China, including Hong Kong, Taiwan, and Macau. Financial details of the agreement have not been disclosed. Energenx was established by Galvanize in collaboration with founding…
-
AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence (acalabrutinib), a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, in China. The drug previously received conditional marketing approval in the country in March this year, specifically for the treatment of mantle cell lymphoma (MCL) that has…
-
Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered into a partnership with a top-tier Indian pharmaceutical company. The collaboration aims to facilitate the regulatory filing, marketing, and distribution of Kangtai Bio’s dual carrier 13-valent pneumonia vaccine in India. Indian Pharmaceutical Company’s Extensive ReachThe…
-
Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China
•
US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics, in the Chinese market. This collaborative platform aims to connect industry, academia, research, and medicine, leveraging existing orthopedic integration platforms, industry chain capabilities, digitalization, and artificial intelligence technologies. With an open and collaborative approach, Medtronic…
-
TYK Medicines Partners with WuXi STA for Comprehensive CMC Services
•
Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), to enhance their collaboration in the field of Chemistry, Manufacturing, and Controls Development (CMC) services. According to the agreement, WuXi STA will serve as a strategic partner to TYK Medicines, offering one-stop services…
-
Beijing’s E-Health Now Secures Tens of Millions in Series B Financing
•
E-Health Now, a comprehensive health management platform headquartered in Beijing, has reportedly raised tens of millions of renminbi in a Series B financing round. The round was led by Orient State-Owned Capital, with additional investments from Ventech China, GSR Ventures, LangRun Investment, and Tongji Fund. E-Health Now’s AI-Powered Digital Healthcare…
-
Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO
•
Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than RMB100 million in a Series A financing round. The round was led by JOLMO, with additional investments from Bondshine Capital, Wei Chi Equity Fund, and Hua Guoping, the founder of Jiangsu Hualan New Pharmaceutical Material…
-
Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions
•
China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese firm Vazyme Biotech Co., Ltd. (SHA: 688105). The collaboration aims to develop a comprehensive automated solution for infection screening and respiratory pathogen detection. Advancing Diagnostic Capabilities with AutomationThe partnership will leverage the combined expertise of…
-
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HS336, intended for the treatment of advanced solid tumors. HS336: A Novel SHP2 Inhibitor for Anti-Tumor TherapyHS336 is a…
-
Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology
•
US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna’s vice-president of finance, as reported by a local media…
-
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
•
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib clinical study of its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ (HKG: 1877, SHA: 688180) PD-1 inhibitor toripalimab for the treatment of hepatocellular carcinoma (HCC) at the American Society of Clinical Oncology (ASCO)…
-
Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST
•
The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib, a Category 1 drug developed by Suzhou Ascentage Pharma Co., Ltd’s (HKG: 6855) wholly-owned subsidiary, Guangzhou Shunjian Biopharmaceutical Technology Co., Ltd. The designation targets succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors (GIST) that have received…
-
Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from a Phase Ib clinical study of its drug ABSK021 (pimicotinib) in the treatment of tenosynovial giant cell tumor (TGCT) at the American Society of Clinical Oncology (ASCO) annual meeting. Impressive Objective Response Rates for PimicotinibThe…
-
Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting
•
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical data for its paclitaxel polymer micelles will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Clinical Data from Retrospective Study in NSCLC TreatmentThe data originates from a retrospective study examining…
-
Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of its four oncology drugs, including olverembatinib, Bcl-2 inhibitor APG-2575, MDM2-p53 inhibitor APG-115, and FAK/ALK/ROS1 triple inhibitor APG-2449, at an upcoming medical conference. Phase I Study for APG-2449 in Solid TumorsAn open, multicenter, dose escalation, and…
-
BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the range of BeiGene’s research expertise and the productivity of one of the industry’s largest research and development teams. The…
